Industry Overview:
The global point-of-care diagnostics market is estimated to reach USD 16,073.4 million in 2025, reflecting a Y-O-Y of 6.9%. Gaining growth from rising demand for rapid infectious disease detection, chronic disease monitoring also emergency diagnostics. Within the market decentralized healthcare accessibility has created intensifying adoption across hospitals, physician offices, ambulatory care centers, pharmacies, retail clinics, and diagnostic laboratories. Rising integration because expand technological innovations such as of multiplex molecular assays, biosensor-enabled handheld monitoring devices, smartphone-connected testing platforms and real-time digital result transmission systems. It is significantly improving diagnostic speed which must be supportive to clinical accuracy, patient accessibility, and workflow efficiency. These is beneficial for reducing dependency on centralized laboratories to accelerating expansion across global healthcare ecosystems.
Industry Insights: Scale, Segments, and Shifts
• Market Size & Growth: The global point-of-care diagnostics market is projected to reach USD 31,032.8 million by 2035, registering a CAGR of 6.8% between 2025 and 2035.
• Segment Analysis: Handheld POC Monitoring Devices hold around 28% share due to rising use in rapid glucose, cardiac, and infectious disease monitoring, while Rapid Diagnostic Test Kits are creating broad marketplace due to increasing adoption in home-based testing and emergency diagnostics.
• Regional Highlights: North America dominant 38% share in 2024 because expand advanced decentralized healthcare infrastructure, while Asia Pacific is expected to lead growth coming year through rising healthcare digitization and expanding rapid diagnostic accessibility.
• Competitive Landscape: The market is moderately consolidated, with key companies such as Abbott, Roche Diagnostics, and Siemens Healthineers leading. These players are focusing to how to offer portable molecular testing systems and cloud-connected diagnostic platforms for enhancing decentralized healthcare capabilities globally.
Factors Shaping the Next Decade
• Market Gaps / Restraints: During the geopolitical disruptions that impacting supply chain of biosensor and semiconductor and high costs required for integration of connected diagnostic platforms remain key restraints for small healthcare providers and emerging manufacturers.
• Key Trends and Innovations: Industry is witness for transformation towards adapting innovations such as CRISPR-based molecular assay platforms, multiplex microfluidic cartridges, and dry-reagent biosensor handheld analyzers. While real-time cloud-connected diagnostic synchronization systems and ultra-low sample volume testing technologies are improving decentralized testing precision and accelerating rapid disease surveillance globally.
• Potential Opportunities: In future increasing development of autonomous pharmacy-based diagnostic kiosks and wearable biosensor-linked predictive screening ecosystems are expected to create significant future market potential. While expansion of disposable lab-on-chip molecular testing platforms for rural healthcare infrastructure will also generate new sustainable revenue opportunities globally.
Recent Industry Updates:
• December 2025: Roche has announced to they get FDA clearance for its cobas® liat molecular point-of-care test for Bordetella infections and it is enabling to PCR-based pertussis detection within 15 minutes to improve rapid infectious disease diagnosis across decentralized healthcare settings.
• August 2025: Roche has launched cobas Respiratory 4-flex powered by TAGS technology it is specially designed for multiplex syndromic PCR testing solution will be able to simultaneous detection of SARS-CoV-2, Influenza A/B, and RSV with customizable respiratory testing workflows.
Industry Outlook Scope:
By Product
• Dipsticks
• Strips & Cards
• Cassettes
• Handheld POC Monitoring Devices
• Benchtop POC Analyzers
• Consumables & Reagents
• Rapid Diagnostic Test Kits
• Others
By Sample Type
• Blood
• Plasma/Serum
• Urine
• Saliva
• Nasal & Throat Swabs
• Sweat
• Others
By End User
• Hospitals
• Clinics & Physician Offices
• Diagnostic Laboratories
• Home Care Settings
• Ambulatory Care Centers
• Long-Term Care Centers
• Government & Federal Agencies
• Non-Governmental Organizations (NGOs)
• Pharmacies & Retail Clinics
• Others
Geographical Insights: Emerging Corridors of Growth
• Regional Overview: While Europe is witnessing for rapid uptake gained through the expansion of decentralized molecular testing networks and integration of rapid diagnostics into national antimicrobial resistance surveillance frameworks, In the Middle East & Africa is creating strong growth momentum through mobile infectious disease screening programs and deployment of portable diagnostics across remote healthcare infrastructure. Latin America is expanding their footprint with provide localized rapid testing manufacturing initiatives and increasing integration of retail-clinic-based diagnostic services across urban healthcare systems.
Download the free regional report sample.
• Countries to Watch: Germany is generating new identity with strong growth due to increasing adoption of hospital-linked rapid molecular testing workflows and Brazil is taking their steps towards high demand through expansion of localized infectious disease diagnostics manufacturing. The UAE is gaining demand because increasing smart hospital investments and integration of portable diagnostic systems.
Regulatory Environment and Policy Support
• Government Regulations & Supportive Policies: Global point-of-care diagnostics providers are aligning with the European Union In Vitro Diagnostic Regulation (IVDR 2017/746) and the U.S. FDA Clinical Laboratory Improvement Amendments (CLIA) waiver framework. It is beneficial for ensure standardized diagnostic validation also decentralized testing reliability and rapid commercialization compliance. These frameworks promoting to adoption of high-sensitivity molecular diagnostics and portable testing platforms across clinical and home healthcare environments.
• Key Government Initiatives: Initiatives such as China’s Healthy China 2030 Plan and Saudi Arabia’s Vision 2030 healthcare transformation strategy. In these way governments supporting to the investment in decentralized diagnostics infrastructure and digital healthcare modernization to accelerate wider adoption of point-of-care diagnostic technologies.
Competitive Landscape and Strategic Outlook
The market is moderately concentrated, with leading players expanding their decentralized molecular testing partnerships and build strong portable biosensor diagnostic portfolios and cloud-connected rapid testing ecosystems. Globally well-established providers are enhancing their market reach through offering multiplex assay commercialization with retail-clinic diagnostic integration and hospital-linked rapid testing workflows. Even the niche innovators are capturing growth through the offering ultra-compact microfluidic analyzers and disposable lab-on-chip platforms. They also trying to provide pharmacy-based self-testing solutions specially designed for faster deployment across distributed healthcare environments.
Industry Competition:
• F. Hoffmann-La Roche Ltd.
• Qiagen
• Danaher Corporation
• Becton Dickinson (BD)
• bioMérieux
• Abbott
• Siemens Healthcare GmbH
• Werfen
• Nova Biomedical
• Trividia Health, Inc.
• QuidelOrtho Corporation
• Trinity Biotech
• Sekisui Diagnostics
• Orasure Technologies, Inc.
• Spectral Medical, Inc.
Analyst Perspective
The point-of-care diagnostics industry is transitioning toward adapting clinically connected, ultra-fast, and patient-centric detection ecosystems trough miniaturized biochemical processing and digitally synchronized care delivery models. During the next three to five years, growth will be expected from expansion of near-patient infectious screening networks with compact multi-disease analytical systems and remote diagnostic interoperability across outpatient environments. In emerging regional participants developing self-contained sample-to-result platforms and low-volume reagent architectures. Increasing adaptive decentralized screening infrastructure are likely to strengthen competitive positioning and unlock substantial long-term commercial opportunities globally.
What to Expect from Outlook:
1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the global point-of-care diagnostics market.
2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the global point-of-care diagnostics market sector.
3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.
4. Add weight to presentations and pitches by understanding the future growth prospects of the global point-of-care diagnostics market with a forecast for the decade by both market share (%) & revenue (USD Million).
1. Introduction
1.1. Executive Summary
1.2. Regional Snapshot
1.3. Market Scope
1.4. Market Definition
2. Across
The Globe
2.1. Factors Affecting End Use Industries
2.2. Market Dynamics
2.2.1. Upcoming Opportunities
2.2.2. Ongoing Market Trends
2.2.3. Growth Driving Factors
2.2.4. Restraining Factors
2.3. Value Chain Analysis
2.3.1. List of Manufacturers
2.3.2. List of Distributors/Suppliers
2.3.3. List of End Users
2.4. PORTER’s & PESTLE Analysis
2.5. Key Developments
2.6. Key Regulations & Certifications
3. Global
Point-of-Care Diagnostics Market Overview, By Product
3.1. Market Size (US$ Mn) Analysis, 2020 –
2035
3.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
3.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
3.3.1. Dipsticks
3.3.2. Strips & Cards
3.3.3. Cassettes
3.3.4. Handheld POC Monitoring Devices
3.3.5. Benchtop POC Analyzers
3.3.6. Consumables & Reagents
3.3.7. Rapid Diagnostic Test Kits
3.3.8. Others
4. Global
Point-of-Care Diagnostics Market Overview, By Sample Type
4.1. Market Size (US$ Mn) Analysis, 2020 –
2035
4.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
4.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
4.3.1. Blood
4.3.2. Plasma/Serum
4.3.3. Urine
4.3.4. Saliva
4.3.5. Nasal & Throat Swabs
4.3.6. Sweat
4.3.7. Others
5. Global
Point-of-Care Diagnostics Market Overview, By End User
5.1. Market Size (US$ Mn) Analysis, 2020 –
2035
5.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
5.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
5.3.1. Hospitals
5.3.2. Clinics & Physician Offices
5.3.3. Diagnostic Laboratories
5.3.4. Home Care Settings
5.3.5. Ambulatory Care Centers
5.3.6. Long-Term Care Centers
5.3.7. Government & Federal Agencies
5.3.8. Non-Governmental Organizations (NGOs)
5.3.9. Pharmacies & Retail Clinics
5.3.10. Others
6. Global
Point-of-Care Diagnostics Market Overview, By Region
6.1. Market Size (US$ Mn) Analysis, 2020 –
2035
6.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
6.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Middle East & Africa
6.3.5. South America
7. North
America Point-of-Care Diagnostics Market Overview
7.1. Market Size (US$ Mn) Analysis, 2020 –
2035
7.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
7.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
7.3.1. By Country
7.3.1.1. U.S.
7.3.1.2. Canada
7.3.1.3. Mexico
7.3.2. By Product
7.3.3. By Sample Type
7.3.4. By End User
8. Europe Point-of-Care Diagnostics Market
Overview
8.1. Market Size (US$ Mn) Analysis, 2020 –
2035
8.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
8.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
8.3.1. By Country
8.3.1.1. UK
8.3.1.2. Italy
8.3.1.3. Spain
8.3.1.4. Germany
8.3.1.5. France
8.3.1.6. BENELUX
8.3.1.7. Nordics
8.3.1.8. Rest of Europe
8.3.2. By Product
8.3.3. By Sample Type
8.3.4. By End User
9. Asia
Pacific Point-of-Care Diagnostics Market Overview
9.1. Market Size (US$ Mn) Analysis, 2020 –
2035
9.2. Market Share (%) Analysis (2024 vs
2035), Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness
Analysis (2025 - 2035)
9.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
9.3.1. By Country
9.3.1.1. China
9.3.1.2. Japan
9.3.1.3. India
9.3.1.4. South Korea
9.3.1.5. ASEAN
9.3.1.6. Australia & New Zealand
9.3.1.7. Rest of Asia Pacific
9.3.2. By Product
9.3.3. By Sample Type
9.3.4. By End User
10. Middle East
& Africa Point-of-Care Diagnostics Market Overview
10.1. Market Size (US$ Mn) Analysis, 2020 – 2035
10.2. Market Share (%) Analysis (2024 vs 2035),
Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness Analysis
(2025 - 2035)
10.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
10.3.1. By Country
10.3.1.1. GCC
10.3.1.2. South Africa
10.3.1.3. Rest of Middle East & Africa
10.3.2. By Product
10.3.3. By Sample Type
10.3.4. By End User
11. South
America Point-of-Care Diagnostics Market Overview
11.1. Market Size (US$ Mn) Analysis, 2020 – 2035
11.2. Market Share (%) Analysis (2024 vs 2035),
Y-o-Y Growth (%) Analysis (2025 - 2035) & Market Attractiveness Analysis
(2025 - 2035)
11.3. Market Absolute $ Opportunity Analysis,
2020 – 2035
11.3.1. By Country
11.3.1.1. Brazil
11.3.1.2. Chile
11.3.1.3. Rest of South America
11.3.2. By Product
11.3.3. By Sample Type
11.3.4. By End User
12. Country-Wise
Market Analysis
12.1. Growth Comparison by Key Countries
13. Competitive
Landscape
13.1. Market Share (%) Analysis, By Top Players
13.2. Market Structure Analysis, By Tier I &
II Companies
14. Company
Profiles
14.1. F. Hoffmann-La Roche Ltd.
14.1.1. Company Overview
14.1.2. Business Segments
14.1.3. Financial Insights
14.1.4. Key Business Aspects (Noise Analysis)
14.2. Qiagen
14.3. Danaher Corporation
14.4. Becton Dickinson (BD)
14.5. bioMérieux
14.6. Abbott
14.7. Siemens Healthcare GmbH
14.8. Werfen
14.9. Nova Biomedical
14.10. Trividia Health, Inc.
14.11. QuidelOrtho Corporation
14.12. Trinity Biotech
14.13. Sekisui Diagnostics
14.14. Orasure Technologies, Inc.
14.15. Spectral Medical, Inc.
15. Analysis
& Recommendations
15.1. Targeting Segment
15.2. Targeting Region
15.3. Market Approach
16. Research
Methodology
17. Disclaimer
